The independent knowledge hub for ibogaine research, safety & policy
At a turning point
Ibogaine is a psychoactive compound derived from the iboga plant, used in Central African spiritual tradition for centuries. Today it sits at the intersection of addiction medicine, neuroscience, and global drug policy — generating serious scientific attention and urgent regulatory debate.
This site exists to make the evidence clear, the risks honest, and the history understood — for patients, clinicians, journalists, and policymakers alike.
Where would you like to start?
Understand what ibogaine treatment involves, what questions to ask any clinic, what the risks are, and how to find medically supervised care. Honest information — not marketing.
Start here →For journalists, policymakers, and clinicians. Cited sources, systematic review summaries, legal status by country, and a policy timeline you can reference and link to.
Research resources →Start from the beginning. What ibogaine is, where it comes from, how it works, and why it's generating serious attention from scientists, veterans' advocates, and governments right now.
The full story →
Science & Research
Only two randomized controlled trials have been conducted on ibogaine for substance use disorders. Reviews from 2022 and 2023 describe preliminary anti-addictive potential — but also significant cardiac risks and a small number of fatalities. Here is what the research actually says, without the hype or the fear.
Read the evidence summary →Explore by topic
01
History & Origins
From Central African forager tribes and Bwiti ceremony to Howard Lotsof's accidental discovery and the rise of underground clinics.
02
The Science
How ibogaine interacts with the brain's opioid, serotonin, and sigma systems — and why its mechanism is unlike any other known compound.
03
Safety & Risks
Cardiac risks, drug interactions, what supervised treatment looks like, and the questions anyone should ask before proceeding.
04
Law & Policy
Legal status country by country. The 2026 US executive order. Texas's $50M program. Where global regulation is heading.
Every claim on this site links to its primary source. We are independent, non-commercial, and have no financial relationship with any treatment clinic, pharmaceutical company, or advocacy organization.
Primary sources only. Peer-reviewed research, official regulatory documents, and verified journalism. No secondary summaries without citation.
Safety is never buried. Risks and fatalities are presented clearly on every relevant page — not in footnotes.
Actively maintained. Policy and research developments are tracked and updated. This is not a static resource.
No affiliation. Independent, non-commercial, and editorially free from any treatment provider or advocacy group.